<DOC>
	<DOCNO>NCT00057785</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Giving radiation therapy different way may cause less damage normal tissue , prevent lessen mouth dryness , may help patient live comfortably . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness specialize radiation therapy technique without chemotherapy reduce mouth dryness patient nasopharyngeal cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy Reducing Mouth Dryness Patients With Nasopharyngeal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine transportability IMRT multi-institutional setting . - Determine rate late xerostomia patient nasopharyngeal cancer treat intensity-modulated radiotherapy ( IMRT ) without chemotherapy . - Correlate reduction side effect salivary flow compliance patient treat regimen . - Determine rate local-regional control , distant metastasis , disease-free overall survival patient treat regimen . - Determine acute late toxicity regimens patient . - Determine chemotherapy compliance patient treat regimen . OUTLINE : Patients undergo daily intensity-modulated radiotherapy ( IMRT ) 5 day week approximately 6.5 week ( total 33 fraction ) absence disease progression unacceptable toxicity . Patients stage T2b great and/or node-positive disease receive cisplatin IV 20-30 minute day 1 , 22 , 43 concurrently IMRT follow cisplatin IV 20-30 minute fluorouracil IV 96 hour start day 71 , 99 , 127 . Quality life assess saliva measurement baseline 3 , 6 , 12 month IMRT . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 64 patient accrue study within 36-40 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIVB squamous cell carcinoma nasopharynx WHO IIII No stage IVC disease No evidence distant metastasis Measurable evaluable disease Must treat primary radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic White blood cell count ( WBC ) least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Not specify Renal Creatinine great 1.6 mg/dL Creatinine clearance least 60 mL/min Other Not pregnant ( If stage T2b great nodepositive disease ) Negative pregnancy test ( If stage T2b great nodepositive disease ) No prior head neck cancer No malignancy within past 5 year except nonmelanoma skin cancer No active untreated infection No major medical psychiatric illness would preclude study entry Nutritional general physical condition compatible radiotherapy NOTE : *If stage T2b great nodepositive disease PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 6 month since prior chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 6 month since prior radiotherapy head neck cancer Surgery No prior head neck surgery primary tumor lymph node except incisional excisional biopsy Other No concurrent experimental therapy cancer No amifostine pilocarpine 3 month radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>oral complication radiation therapy</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
</DOC>